Advertisement

Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals

Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study*

  1. Signe W. Worm, MD1,
  2. Caroline A. Sabin, PHD2,
  3. Peter Reiss, PHD3,
  4. Wafaa El-Sadr, MD, MPH4,
  5. Antonella d'Arminio Monforte, DMSC5,
  6. Christian Pradier, MD6,
  7. Rodolphe Thiebaut, PHD7,
  8. Matthew Law, PHD8,
  9. Martin Rickenbach, MD9,
  10. Stephane De Wit, PHD10,
  11. Jens D. Lundgren, DMSC1 and
  12. Nina Friis-Møller, PHD1
  1. 1Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
  2. 2Royal Free and University College, London, U.K.
  3. 3Academic Medical Center, Amsterdam, the Netherlands
  4. 4Harlem Hospital Center, Division of Infectious Diseases, New York, New York
  5. 5University of Milan, Milan, Italy
  6. 6Hôpital Archet 1, Nice, France
  7. 7Université Victor Segalen, Bordeaux, France
  8. 8National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia
  9. 9University Hospital, Lausanne, Switzerland
  10. 10University Hospital St. Pierre, Brussels, Belgium
  1. Corresponding author: Signe W. Worm, sww{at}cphiv.dk

Abstract

OBJECTIVE—It is much debated whether the metabolic syndrome contributes additional information over and above that provided by the individual components of the syndrome alone. Among HIV-infected individuals, we investigated whether any particular combinations of the components included in the definition of the metabolic syndrome are associated with a higher risk of cardiovascular disease (CVD).

RESEARCH DESIGN AND METHODS—We followed 33,347 HIV-infected individuals in a prospective observational study. The effect of combinations of components of the metabolic syndrome (low HDL cholesterol, high triglycerides, high BMI, hypertension, and diabetes) on the risk of CVD was assessed by Poisson regression incorporating interactions between each component pair and adjusting for age, sex, family history of CVD, smoking status, calendar year, and exposure to antiretroviral therapy. We reduced the risk of type 1 errors by randomly splitting the data set for training (70% of sample) and validation (remaining 30%).

RESULTS—In the training data set, 671 patients experienced a CVD event over 110,652 person-years. Unadjusted, the presence of metabolic syndrome at study enrollment (≥3 of the factors) was associated with a 2.89 higher risk of CVD (95% CI 2.34–3.59; P = 0.0001) compared with individuals without the metabolic syndrome. After adjustment for the individual components, the metabolic syndrome as an entity no longer predicted the risk of CVD (adjusted relative risk 0.85; 95% CI 0.61–1.17; P = 0.32). No significant positive interactions were found among the components of the metabolic syndrome.

CONCLUSIONS—The presence of the metabolic syndrome in HIV-infected individuals did not appear to increase the CVD risk over and above that conferred by the components of the syndrome separately.

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 3 December 2008.

  • *

    * A full list of members of the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study is available in an online appendix.

  • Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

    • Accepted November 20, 2008.
    • Received July 28, 2008.
| Table of Contents

This Article

  1. Diabetes Care March 2009 vol. 32 no. 3 474-480
  1. Online-Only Appendix
  2. All Versions of this Article:
    1. dc08-1394v1
    2. 32/3/474 most recent
Advertisement